Devonian Health Group (GSD) Q1 2025 earnings summary

Executive summary

• First quarter revenues rose 360% year over year, driven by strong uptake of DEXLANSOPRAZOLE at Altius Healthcare.

• Net loss narrowed to $0.362 million ($0.002 per share) from $0.721 million ($0.005 per share) year over year.

• Cash position improved to $12.5 million, with debt stable at $2.1 million as of October 31, 2024.

• 1,535,715 stock options granted to independent directors at an exercise price of $0.19, exercisable for 10 years.

Financial highlights

• Distribution revenue reached $5.85 million in Q1, up 360% year over year due to DEXLANSOPRAZOLE launch.

• Net loss for the quarter was $0.362 million, a significant improvement from the prior year's $0.721 million loss.

• Cash and cash equivalents increased to $12.5 million from $9.9 million at the start of the fiscal year.

Outlook and guidance

• Preparations underway for phase II/III clinical study of Thykamine for pediatric atopic dermatitis.

• Management highlights ongoing scientific activities and expects continued financial support from Altius revenue.

• Forward-looking statements caution about risks and uncertainties affecting future results.